follow
decad
research
scientist
develop
larg
number
drug
therapeut
agent
use
reduc
symptom
sever
number
neuroimmunolog
diseas
multipl
sclerosi
ms
neuriti
myasthenia
gravi
howev
none
treatment
methodolog
cur
mani
limit
life
span
interferon
ifn
induc
neutral
antibodi
ms
patient
caus
seriou
side
effect
progress
multifoc
leucoencephalopathi
monoclon
antiveri
late
antigen
vla
antibodi
natalizumab
thu
caus
patient
drop
clinic
trial
stop
take
treatment
addit
although
mani
studi
dissect
intric
pathway
involv
aetiolog
develop
pathogenesi
diseas
ms
still
definit
understand
diseas
manifest
inde
case
ms
whether
singl
diseas
rather
spectrum
disord
similar
characterist
therefor
research
use
anim
model
aid
understand
diseas
pathway
immun
cell
function
patholog
exampl
import
anim
model
demonstr
cell
specif
myelin
epitop
inject
anim
suffici
induc
central
nervou
system
cn
demyelin
diseas
cn
lesion
similar
observ
ms
addit
model
use
preclin
aid
develop
novel
therapeut
agent
mani
differ
anim
model
neuroimmunolog
disord
develop
last
decad
success
howev
import
understand
advantag
limit
model
ensur
correct
model
use
purpos
studi
review
provid
overview
current
avail
neuroimmunolog
diseas
anim
model
describ
advantag
disadvantag
well
relationship
correl
human
diseas
attempt
model
although
one
anim
model
complet
ident
human
diseas
nevertheless
use
import
tool
increas
understand
neuroimmunolog
diseas
use
correctli
ms
human
inflammatori
demyelin
diseas
cn
characterist
demyelin
lesion
contain
immun
cell
infiltr
activ
cnsresid
cell
locat
white
matter
brain
spinal
cord
therefor
studi
investig
patholog
difficult
often
reli
autopsi
tissu
case
patient
might
diseas
decad
therefor
tissu
repres
diseas
end
stage
furthermor
epidemiolog
studi
suggest
initi
factor
ms
might
infect
occur
childhood
therefor
anim
model
ms
critic
studi
suscept
diseas
initi
patholog
earli
stage
diseas
experiment
autoimmun
encephalomyel
eae
autoimmun
cellmedi
diseas
cn
mediat
primarili
cell
commonli
use
anim
model
studi
ms
diseas
character
perivascular
lesion
contain
inflammatori
infiltr
nerv
conduct
block
caus
revers
hindlimb
paralysi
addit
latestag
eae
anim
also
develop
axon
demyelin
loss
patholog
hallmark
ms
lead
sever
perman
disabl
character
immun
cell
infiltr
cell
b
cell
activ
macrophag
microglia
patholog
perivascular
demyelin
lesion
shown
similar
human
ms
lesion
although
eae
spinal
cord
target
organ
wherea
ms
brain
often
target
especi
white
matter
howev
eae
use
model
studi
inflammatori
stage
ms
share
characterist
ms
optic
neuriti
increas
suscept
femal
perivascular
lesion
axon
demyelin
partial
remyelin
well
eventu
axon
loss
flaccidlimb
paralysi
two
commonli
use
model
eae
activ
eae
induc
subcutan
immun
genet
suscept
anim
usual
rodent
myelin
antigen
freund
complet
adjuvantcontain
miner
oil
mycobacterium
tuberculosi
strain
eae
lowrespond
mous
strain
addit
inject
pertussi
toxin
requir
induct
phase
myelinspecif
cell
activ
antigenpres
cell
apc
present
myelin
peptid
fragment
drain
lymph
node
produc
helper
type
cytokin
interferon
ifn
tumour
necrosi
factor
tnf
allow
escap
lymph
node
traffic
cn
effector
phase
diseas
involv
extravas
activ
myelinspecif
cell
bloodbrain
barrier
perivascular
space
spinal
cord
encephalitogen
cell
encount
cnsresid
cell
mediat
stimul
proinflammatori
cytokin
chemokin
mediat
secondari
influx
peripher
inflammatori
cell
includ
b
cell
mononuclear
phagocyt
studi
eae
viral
model
ms
demonstr
apc
cn
restimul
myelinspecif
cell
initi
epitop
spread
myelin
antigen
perpetu
diseas
consequ
proinflammatori
cytokin
milieu
demyelin
cn
axon
thought
mediat
part
numer
mechan
includ
phagocytosi
activ
mononuclear
cell
destruct
effect
antimyelin
antibodi
product
free
radic
direct
cytotox
effect
proinflammatori
cytokin
secret
activ
cell
monocyt
initi
guinea
pig
rat
anim
choic
eae
studi
howev
advent
transgen
gene
knockout
technolog
mice
becom
commonli
use
anim
eae
studi
numer
mous
model
eae
develop
differenti
strain
mous
use
immunodomin
myelin
peptid
particular
strain
commonli
use
eaesuscept
mous
strain
includ
sjl
swr
biozzi
abh
depend
upon
immun
myelin
antigen
mous
strain
use
differ
form
eae
induc
commonli
use
model
sjl
mice
immun
proteolipid
protein
plp
induc
relapsingremit
form
diseas
common
form
ms
mice
immun
myelin
oligodendrocyt
protein
mog
initi
chronicprogress
type
eae
strain
biozzi
abh
mice
immun
suspens
whole
biozzi
abh
spinal
cord
develop
reproduc
relapsingremit
diseas
clinic
symptom
eae
usual
develop
day
postimmun
includ
weight
loss
loss
tail
tone
gait
eventu
paralysi
either
hind
limb
weight
loss
preced
onset
diseas
symptom
thu
use
marker
diseas
onset
daili
observ
eae
symptom
bodi
weight
noninvas
therefor
great
advantag
research
allow
diseas
process
follow
especi
studi
effect
drug
treatment
note
mous
strain
resist
eae
aj
akr
nzw
addit
import
environment
factor
thought
multipl
predispos
genet
element
might
involv
suscept
ms
review
eber
therefor
backcross
eaeresist
mice
eaesuscept
strain
use
genet
suscept
studi
second
model
eae
passiv
involv
vitro
restimul
encephalitogen
cell
myelin
peptid
use
immun
origin
tcell
donor
anim
success
cultur
cell
usual
requir
addit
cytokin
cell
suffici
activ
intraven
administ
anim
traffic
cn
induc
diseas
cn
patholog
diseas
cours
similar
activ
eae
abil
mbpspecif
cell
induc
eae
rat
mice
earliest
evid
suggest
ms
autoimmun
aetiolog
anoth
evid
autoimmun
inflammatori
pathogenesi
includ
presenc
mhc
class
iirestrict
cell
recogn
myelin
antigen
myelin
basic
protein
mbp
plp
mog
ms
patient
well
healthi
individu
mhc
class
ii
gene
associ
ms
suscept
cell
alreadi
activ
administ
anim
passiv
eae
suitabl
model
investig
effector
phase
diseas
advantag
passiv
eae
immun
step
requir
thu
antigen
reserv
continu
activ
cell
like
boost
immun
system
nonspecif
furthermor
direct
inject
effector
cell
mice
allow
definit
start
point
diseas
induct
known
might
use
treatment
studi
final
encephalitogen
cell
directli
track
vivo
studi
method
extravas
cn
isol
antigenspecif
cell
earli
studi
demonstr
activ
myelinspecif
cell
secret
encephalitogen
suffici
induc
eae
transfer
mice
suscept
genet
background
howev
knockout
gene
encod
exacerb
eae
therefor
role
eae
straightforward
product
cnsinfiltr
cell
import
bloodbrain
barrier
dysfunct
lesion
format
ms
patient
genet
inhibit
mice
suffici
partli
amelior
eae
mice
indic
cell
altern
effector
tcell
subset
might
critic
effector
cell
eae
inde
cell
cultur
presenc
cytokin
becom
highli
pathogen
induc
eae
transfer
mice
cell
show
enhanc
effici
induc
eae
compar
cell
therefor
might
requir
less
cell
manipul
vitro
adopt
transfer
studi
although
predomin
eae
paper
investig
role
myelinspecif
cell
eae
ms
lesion
report
contain
greater
number
cell
compar
cell
howev
function
cell
ms
lesion
unclear
therefor
studi
cell
eae
import
number
eae
model
induc
mhc
class
ispecif
cell
report
tcell
clone
isol
mbpimmun
wildtyp
mice
induc
eae
numer
neurolog
deficit
ataxia
spastic
reflex
spin
well
hindlimb
paralysi
intraven
inject
wildtyp
mice
form
eae
sever
mice
moribund
day
interestingli
model
show
differ
clinic
symptom
cellmedi
type
eae
importantli
similar
ms
perivascular
lesion
predomin
brain
compar
eae
perivascular
lesion
locat
spinal
cord
anoth
studi
report
cell
line
could
also
induc
sever
chronic
form
eae
adopt
transfer
mice
contrast
mbpinduc
tcell
model
eae
lesion
present
spinal
cord
brain
differ
genet
background
avail
myelin
antigen
cn
induct
procedur
might
explain
differ
observ
two
model
contrast
earli
studi
recent
investig
indic
inhibitori
role
cell
eae
neuroantigenspecif
autoregulatori
cell
inhibit
autoimmun
demyelin
modul
dendrit
cell
function
cell
amelior
eae
reduc
product
cell
human
mous
model
also
develop
studi
effect
msrelat
myelin
epitop
present
cell
human
hla
molecul
show
present
hlaa
mogspecif
cell
exacerb
cellinduc
eae
overal
model
cellinduc
eae
import
determin
function
cell
cn
autoimmun
diseas
ie
patholog
versu
inhibitoryregulatori
effect
advantag
cellinduc
eae
target
organ
predominantli
brain
similar
ms
advantag
eae
robust
reproduc
diseas
cours
use
studi
earli
stage
diseas
initi
activ
immun
cell
especi
antigenspecif
cell
well
mechan
effector
phase
role
resid
cn
cell
regulatori
cell
regulatori
mechan
addit
patholog
studi
stage
diseas
provid
import
inform
regard
site
mechan
demyelin
remyelin
nerv
conduct
block
axon
loss
furthermor
depend
upon
model
use
differ
mechan
involv
relaps
vs
chronic
form
diseas
studi
reader
encourag
read
review
articl
describ
specif
induct
protocol
numer
eae
model
avail
signific
disadvantag
eae
locat
patholog
spinal
cord
unlik
ms
mani
lesion
occur
brain
furthermor
although
eae
clearli
autoimmun
diseas
ms
hallmark
autoimmun
diseas
evid
specif
immunodomin
myelin
antigen
lack
although
cell
critic
diseas
induct
eae
model
role
ms
less
clear
mani
type
immun
cell
cell
b
cell
monocyt
probabl
also
import
role
exampl
b
cell
littl
role
mani
eae
model
least
earli
time
point
usual
studi
howev
import
ms
suggest
benefici
effect
therapi
ms
patient
eae
use
tool
test
potenti
new
immunomodulatori
therapi
although
four
approv
ms
treatment
studi
eae
natalizumab
mitoxantron
glatiram
acet
fingolimod
larg
major
new
treatment
fail
enter
ms
clinic
trial
explan
might
treatment
studi
use
eae
model
mimic
patient
diseas
cours
clinic
exampl
administr
drug
initi
eae
diseas
use
indic
effect
activ
cell
real
clinic
signific
ms
treatment
patient
often
experienc
symptom
time
treatment
start
addit
treatment
administ
onset
symptom
prevent
paralysi
often
said
prevent
demyelin
howev
treatment
immunomodulatori
difficult
differenti
antidemyelin
immunosuppress
effect
therefor
potenti
treatment
administ
onset
eae
symptom
clinic
meaning
result
summari
although
eae
imperfect
model
ms
correct
usag
investig
critic
studi
novel
therapeut
compound
number
etiolog
studi
indic
potenti
role
virus
suscept
onset
exacerb
ms
therefor
addit
immun
model
use
investig
earli
immunolog
pathway
involv
pathogenesi
number
virusinduc
demyelin
model
develop
allow
studi
potenti
viral
aetiolog
ms
use
model
number
hypothes
mechan
diseas
onset
develop
includ
molecular
mimicri
epitop
spread
direct
bystand
activ
releas
cryptic
epitop
semliki
forest
viru
sfv
strain
neurotrop
singlestrand
rna
alphaviru
togavirida
famili
induc
demyelin
diseas
upon
intraperiton
inject
sjlj
mice
diseas
character
virusinduc
demyelin
cn
despit
clearanc
viru
immun
system
maxim
demyelin
lesion
express
observ
day
postinfect
month
balbc
mice
wherea
demyelin
proinflammatori
cytokin
express
detect
sjlj
mice
year
sfv
infect
induc
mbpspecif
tcell
respons
demyelin
mediat
cell
mhv
group
ii
positivestrand
rna
coronaviru
natur
pathogen
mice
upon
intracrani
inject
caus
acut
encephalomyel
develop
chronic
cn
immunemedi
demyelin
diseas
clinic
patholog
similar
ms
mhv
induc
either
acut
chronic
form
diseas
acut
form
character
product
proinflammatori
cytokin
chemokin
eventu
reduc
mhv
viral
load
cn
howev
persist
infect
spinal
cord
white
matter
tract
propag
promot
antivir
respons
caus
demyelin
lead
symptom
limp
tail
partial
complet
hindlimb
paralysi
similar
eae
contrast
eae
viral
model
cn
demyelin
diseas
myelinspecif
cell
epitop
spread
thought
requir
demyelin
rather
persist
effect
antivir
immun
respons
includ
macrophag
cell
caus
chronic
demyelin
review
lane
summari
tmevidd
demyelin
model
associ
persist
infect
cn
wherea
sfv
infect
sjl
mice
might
repres
model
ms
immunemedi
demyelin
trigger
viru
infect
cn
clear
effici
host
immun
system
although
studi
indic
ms
might
viral
aetiolog
mechan
involv
unknown
might
involv
infect
earli
life
prime
autoreact
cell
molecular
mimicri
persist
infect
cn
caus
demyelin
via
epitop
spread
andor
molecular
mimicri
thu
mous
model
allow
studi
virus
might
induc
cn
demeylin
autoimmun
diseas
contrast
mhv
provid
differ
scope
studi
underli
mechan
mediat
host
defenc
acut
viral
infect
later
becom
chronic
associ
cn
demyelin
neurolog
symptom
absenc
myelinspecif
tcell
respons
experiment
autoimmun
neuriti
ean
commonli
use
robust
highli
predict
anim
model
gb
origin
develop
rabbit
sinc
induc
wide
varieti
anim
includ
rat
mice
rabbit
guinea
pig
monkey
diseas
induc
activ
immun
suscept
anim
purifi
whole
peripher
nerv
myelin
specif
myelin
protein
compon
myelin
protein
myelin
protein
zero
complet
freund
adjuv
ean
rat
mice
monophas
acut
demyelin
inflammatori
diseas
peripher
nervou
system
mani
similar
gb
includ
clinic
immunolog
morpholog
characterist
rat
onset
diseas
observ
postimmun
peak
diseas
sever
day
clinic
diseas
character
tail
limb
weak
histopatholog
analys
shown
presenc
nerv
oedema
demyelin
peripher
nerv
accompani
infiltr
inflammatori
cell
featur
present
gb
symptom
like
caus
combin
nerv
conduct
block
effect
demyelin
effector
phase
ean
diseas
typic
proinflammatori
compon
includ
chemokin
rant
review
fujioka
cytokin
review
zhu
adhes
molecul
shown
upregul
cytokin
might
mediat
demyelin
peripher
nerv
evid
show
addit
enhanc
ean
wherea
blockad
neutral
antibodi
amelior
ean
symptom
diseas
cours
ean
mous
model
sever
clinic
symptom
patholog
featur
similar
rat
ean
also
report
earli
studi
report
induct
ean
sjlj
mice
show
subclin
damag
peripher
nerv
myelin
without
clinic
symptom
contrast
ean
lewi
rat
develop
typic
hindlimb
weak
histopatholog
peripher
nervou
system
subsequ
studi
demonstr
addit
pertussi
toxin
sjlj
mice
immun
bovin
peripher
nerv
myelin
complet
freund
adjuv
enhanc
mild
diseas
seen
absenc
pertussi
toxin
immun
mice
pertussi
toxin
treat
recombin
mous
diseas
cours
durat
prolong
recoveri
delay
histolog
analysi
demonstr
sever
demyelin
cauda
equina
sciatic
nerv
recoveri
stage
well
mononuclear
cell
infiltr
note
although
mice
initi
thought
resist
ean
induct
immun
male
mice
synthet
peptid
induc
clinic
patholog
characterist
acut
monophas
ean
previous
shown
addit
intraven
administr
pertussi
toxin
increas
incid
ean
enhanc
inflamm
demyelin
peripher
nerv
similar
seen
eae
addit
immun
model
ean
adopt
transfer
model
ean
report
cell
line
shown
transfer
histopatholog
similar
ean
syngen
lewi
rat
recipi
inject
intraven
howev
onset
diseas
earlier
day
transfer
ean
model
compar
activ
immun
ean
model
day
although
ean
robust
reproduc
model
neuriti
share
mani
patholog
clinic
featur
gb
one
critic
disadvantag
campylobact
jejuni
infect
thought
involv
high
percentag
human
case
gb
induc
diseas
rat
furthermor
immun
rat
variou
gangliosid
main
immunolog
target
immun
system
campylobact
jejuniinduc
gb
also
induc
diseas
addit
gangliosid
immun
protocol
fail
enhanc
effect
ean
sever
diseas
onset
although
speci
anim
shown
promis
term
develop
conduct
block
rabbit
immun
demonstr
sciatic
nerv
conduct
block
chicken
administ
campylobact
jejuni
isol
chines
patient
show
sciatic
nerv
wallerian
degener
minor
demyelin
model
studi
extens
therefor
exist
ean
model
use
studi
relat
effector
phase
immunemedi
mechan
peripher
nerv
demyelin
less
use
studi
determin
pathogen
mechan
involv
follow
campylobact
jejuni
infect
experiment
autoimmun
myasthenia
gravi
eamg
origin
induc
rabbit
immun
highli
purifi
achr
isol
electr
organ
electrophoru
electricu
emulsifi
complet
freund
adjuv
induc
product
antibodi
specif
recogn
achr
bind
receptor
nmj
subsequ
block
neurotransmiss
caus
muscl
fatigu
weak
mimic
symptom
observ
human
mg
sinc
first
descript
eamg
induc
wide
varieti
anim
includ
rabbit
rat
mice
guinea
pig
goat
monkey
frog
current
rat
mous
model
anim
model
choic
gene
knockout
transgen
technolog
allow
greater
indepth
investig
specif
molecul
involv
diseas
pathogenesi
suscept
rat
strain
includ
lewi
fischer
wistarmunich
rat
nonrespond
strain
includ
wistar
furth
copenhagen
rat
import
note
mous
strain
differ
suscept
eamg
haplotyp
strain
sjlj
high
respond
wherea
p
haplotyp
nonrespond
therefor
import
determin
strain
use
initi
studi
interestingli
rat
appear
suscept
eamg
mice
usual
one
immun
achr
complet
freund
adjuv
requir
induc
autoantibodi
achr
contrast
suscept
mous
strain
usual
requir
two
three
immun
achr
complet
freund
adjuv
furthermor
diseas
sever
mous
eamg
reduc
compar
rat
model
therefor
import
consider
efficaci
novel
therapeut
agent
test
note
suscept
mg
eamg
link
hlamhc
region
thu
eamg
mani
clinic
patholog
similar
human
mg
especi
presenc
autoantibodi
recogn
bind
achr
follow
immun
cell
mediat
product
achrspecif
antibodi
murin
eamg
well
human
mg
treatment
antiia
antibodi
block
induct
induc
remiss
eamg
evid
role
cell
eamg
pathogenesi
shown
use
lymphocyt
immunosuppress
agent
oral
toler
achr
inhibit
diseas
onset
similar
observ
eae
role
proinflammatori
cytokin
includ
also
import
onset
eamg
function
relat
tcell
develop
prolifer
differenti
studi
eamg
demonstr
treatment
eamg
rat
mice
treatment
reduc
eamg
develop
significantli
improv
establish
diseas
confirm
role
tnf
mg
demonstr
trial
investig
use
tnf
inhibitor
etanercept
mg
patient
reduc
muscl
weak
autoreact
cell
becom
activ
stimul
b
cell
produc
secret
antiachr
antibodi
induc
observ
clinic
symptom
eamg
studi
indic
follow
bind
achr
antibodi
nmj
complement
activ
includ
deposit
membran
attack
complex
might
mediat
destruct
nmj
plasma
membran
confirm
role
complement
eamg
shown
studi
report
blockad
complement
system
complement
inhibitor
protect
rat
induct
eamg
importantli
role
complement
indic
human
mg
indic
valid
eamg
clinic
sign
activ
eamg
tremor
hunch
postur
muscl
weak
fatigu
usual
occur
day
second
immun
mice
observ
sign
muscl
weak
pawgrip
test
least
week
addit
number
test
develop
assess
extent
diseas
includ
quantit
measur
muscl
weak
electromyographi
evalu
eamg
induct
quantif
muscl
achr
loss
serum
antiachr
antibodi
level
radioimmunoassay
elisa
therefor
activ
eamg
use
model
myasthenia
gravi
extent
diseas
measur
use
fairli
noninvas
techniqu
anoth
method
induct
eamg
passiv
transfer
model
autoantibodi
specif
achr
donor
achrimmun
anim
inject
daili
anim
first
shown
rat
model
anoth
method
passiv
induct
eamg
inject
achrspecif
antibodi
isol
serum
mg
patient
interestingli
transfer
eamg
autoreact
lymphocyt
less
robust
autoantibodi
indic
autoreact
antibodi
probabl
major
mechan
involv
onset
nmj
destruct
summari
activ
eamg
use
investig
induct
phase
diseas
bcell
activ
autoantibodi
product
includ
loss
selftoler
mechan
antigenspecif
immun
respons
induct
modul
therapeut
agent
induc
toler
immunosuppress
wherea
passiv
eamg
use
studi
effector
phase
diseas
includ
igg
deposit
nmj
complement
molecul
investig
treatment
use
regulatori
protein
prevent
degrad
nmj
clinic
diseas
passiv
model
eamg
similar
observ
activ
eamg
therefor
serv
use
model
mg
full
activ
immun
system
requir
seen
follow
activ
immun
protocol
although
mg
patient
develop
autoreact
antibodi
achr
approxim
mg
patient
achr
antibodi
neg
howev
mg
patient
antibodi
recogn
musclespecif
kinas
musk
musk
tyrosin
kinas
receptor
involv
develop
postsynapt
membran
nmj
howev
whether
musk
antibodi
involv
pathogen
mg
unclear
unknown
whether
contribut
muscl
weak
therefor
use
anim
model
use
help
dissect
potenti
pathogen
function
musk
antibodi
recent
studi
demonstr
immun
rabbit
mice
musk
ectodomain
induc
muscl
weak
measur
electromyograph
analysi
flaccid
paralysi
similar
human
mg
howev
appear
diseaserel
symptom
longer
achract
achrpass
model
eamg
passiv
transfer
musk
antibodi
less
effect
equival
achrpass
model
therefor
musk
antibodyrel
mg
might
repres
subtyp
mg
reflect
differ
environment
genet
suscept
factor
eamg
use
anim
model
studi
pathway
involv
diseas
pathogenesi
well
investig
novel
therapeut
strategi
importantli
eamg
share
similar
symptom
mg
especi
muscl
weak
fatigu
furthermor
share
immunopatholog
featur
achrspecif
antibodi
serum
muscl
achr
loss
presenc
complement
factor
nmj
support
role
b
cell
regard
autoantibodi
product
one
major
differ
eamg
mg
involv
thymu
loss
selftoler
human
mg
absent
eamg
toler
must
broken
immun
autoantigen
complet
freund
adjuv
although
mani
therapeut
strategi
demonstr
benefici
eamg
translat
clinic
human
mg
might
due
human
form
diseas
complex
aetiolog
eamg
howev
eamg
still
import
role
play
preclin
studi
whether
investig
pathogen
mechan
potenti
therapeut
strategi
despit
numer
benefici
advanc
research
human
neuroimmun
diseas
underli
mechan
mani
diseas
process
still
unclear
hinder
search
cur
therapi
although
use
human
tissu
sampl
critic
type
studi
often
invas
provid
indic
singl
time
point
within
diseas
process
might
ongo
year
decad
therefor
vital
use
anim
model
fill
gap
analys
research
use
human
tissu
howev
whilst
anim
model
diseas
provid
use
inform
import
note
singl
model
perfect
model
human
counterpart
advantag
disadvantag
therefor
import
use
correct
model
studi
involv
ie
immun
cell
activ
mechan
demyelin
immun
cell
traffick
target
organ
induct
vs
effector
phase
diseas
routin
drug
test
addit
import
rememb
mous
strain
use
genet
repres
singl
human
individu
therefor
multipl
strain
ideal
use
develop
novel
treatment
investig
pathogen
mechan
reduc
possibl
strain
irregular
confound
result
